Rituxan (rituximab) - Roche
Doptelet (avatrombopag) - SOBI
Dialysis-Requiring Thrombotic Microangiopathy and Catastrophic Antiphospholipid Syndrome After Avatrombopag Exposure (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0440; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Treatment included pulse methylprednisolone, IVIg, rituximab, anticoagulation, and renal replacement therapy. CAPS should be considered in patients with rapidly progressive multiorgan dysfunction and TMA after prothrombotic triggers. Kidney biopsy is critical in establishing the diagnosis, and recovery of kidney function is possible despite prolonged renal replacement therapy." 
Acute Kidney Injury • Bipolar Disorder • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Epilepsy • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Ischemic stroke • Nephrology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4556118
 
Babasola Sola - Oladokun; Blathnaid O'Connell; Nick Mayer; Michael Clarkson; Maeve P. Crowley; Sarah Margaret Moran
 
Oct 2, 2026
 
Prev Next